Sol-Gel Technologies Ltd. (SLGL) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Sol-Gel Technologies Ltd. (SLGL) closed at USD 68.70 on 2026-10-15, a change of +85.7 % over the past year, with a market capitalization of USD 210.35M.

Sol-Gel Technologies Ltd. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Sol-Gel Technologies Ltd. key figures

Previous close

USD 68.70 (2026-10-15)

1-year change

+85.7 %

Market cap

USD 210.35M

Enterprise value

USD 163.2M

P/E ratio (trailing)

-11.45

P/E ratio (forward)

-8.00

EPS (trailing)

-5.61

EPS (forward)

-8.03

PEG ratio

n/a

Price to book

4.37

Revenue growth

-96.6 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

2.55

Employees

28

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Sol-Gel Technologies Ltd.

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat olmsted syndrome. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Sol-Gel Technologies Ltd. and compare it with other stocks.